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Introduction: Breast tumors are comprised of distinct cancer cell populations which differ in their tumorigenic and
metastatic capacity. Characterization of cell surface markers enables investigators to distinguish between cancer
stem cells and their counterparts. CD24 is a well-known cell surface marker for mammary epithelial cells isolation,
recently it was suggested as a potential prognostic marker in a wide variety of malignancies. Here, we demonstrate
that CD24+ cells create intra-tumor heterogeneity, and display highly metastatic properties.
Methods: The mammary carcinoma Mvt1 cells were sorted into CD24− and CD24+ cells. Both subsets were
morphologically and phenotypically characterized, and tumorigenic capacity was assessed via orthotopic
inoculation of each subset into the mammary fat pad of wild-type and MKR mice. The metastatic capacity of each
subset was determined with the tail vein metastasis assay. The role of CD24 in tumorigenesis was further examined
with shRNA technology. GFP-labeled cells were monitored in vivo for differentiation. The genetic profile of each
subset was analyzed using RNA sequencing.
Results: CD24+ cells displayed a more spindle-like cytoplasm. The cells formed mammospheres in high efficiency
and CD24+ tumors displayed rapid growth in both WT and MKR mice, and were more metastatic than CD24- cells.
Interestingly, CD24-KD in CD24+ cells had no effect both in vitro and in vivo on the various parameters studied.
Moreover, CD24+ cells gave rise in vivo to the CD24− that comprised the bulk of the tumor. RNA-seq analysis
revealed enrichment of genes and pathways of the extracellular matrix in the CD24+ cells.
Conclusion: CD24+ cells account for heterogeneity in mammary tumors. CD24 expression at early stages of the
cancer process is an indication of a highly invasive tumor. However, CD24 is not a suitable therapeutic target;
instead we suggest here new potential targets accounting for early differentiated cancer cells tumorigenic capacity.Introduction
Breast tumors frequently comprise heterogeneous cancer cells
with distinct morphologic and phenotypic features [1, 2].
Intra-tumor heterogeneity can arise from stochastic genetic
or epigenetic changes, or can be attributed to signals from
the stroma within the tumor [3, 4]. More recently, the can-
cer stem-cell hypothesis was proposed to explain these can-
cer cells heterogeneity and hierarchical organization [5, 6].
From a clinical perspective, targeting specific cell lineage
with metastatic proclivity remains a life-saving therapeutic* Correspondence: derek.leroith@mssm.edu
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a poor prognosis with decreased disease-free survival.
The variable expression of cell surface markers among
cancer cells is being widely exploited to identify, isolate
and characterize distinct cancer cell populations [7, 8].
CD24, an anchored cell surface glycoprotein was re-
cently identified as an ideal marker to isolate pure mam-
mary epithelial cells that can be further isolated, along
with staining for other cell surface markers, into stem/
progenitor cells. In line with that finding, isolated Lin−
CD24+CD49f murine mammary cells have been shown
capable of generating functional mammary tissue in vivo
[9, 10]. As a ligand of p-selectin, CD24 serves as an ad-
hesion molecule that facilitates the metastatic process by
supporting the rolling of cancer cells on activated platelets
and endothelial cells [11, 12]. Recently it was suggestedarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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volved in regulating cancer cell proliferation and gene
expression. However the mechanisms mediating these ef-
fects remain elusive [13].
Based on CD24 expression, we have recently identified
two distinct subpopulations in the mammary carcinoma
Mvt-1 cell line, which is derived from a primary mam-
mary tumor in MMTV-VEGF/c-myc bi-transgenic fe-
male mice. Although several studies suggest that it is the
lack of CD24 expression that characterizes breast cancer
stem cells [14, 15], it is known that cell-surface markers
are not conserved among different tumors, due to differ-
ences in the driver mutations [4]. Several questions re-
main to be on the role of CD24 in cancer and more
specifically in tumor heterogeneity. First, does CD24 ac-
tively mediate tumorigenesis, or does it serve only as a
surface marker for tumorigenic cells? Answering this
would facilitate the design of better therapeutic strategies,
i.e., inhibition/downregulation of CD24 or alternatively
exploiting its expression for targeting specific cancer cells.
Second, do CD24+ cells act as stem/progenitor cells and
are CD24− cancer cells their progeny? Finally, are there
specific genes that will discriminate between CD24− and
CD24+ cells, and are there changes at the protein level in
these subpopulations such as phosphorylation that result
in activation of different signaling pathways?
To begin to elucidate the cellular differences between
distinct cancer cell subpopulations, we isolated two can-
cer cell subpopulations based on CD24 expression and
phenotypically characterized these cell subsets. Next, we
turned to mouse models to determine the tumorigenic
capacity of each subset. To investigate the role of CD24
in mediating tumorigenesis, we knocked down CD24 ex-
pression with an shRNA construct. In addition, we dem-
onstrated a degree of hierarchy and plasticity in these
cancer cells. We further analyzed the gene expression
profile of each cell subset and tested the implication of
these findings in vivo.
Our results suggest that CD24 cell surface expression
on mammary epithelial cancer cells identify a subpopu-
lation of cells that is enriched with stem/progenitor-cell
properties. These CD24+ cells display highly tumorigenic
properties with high metastatic capacity; moreover, these
cells can differentiate in vivo, hence creating intra-tumor
heterogeneity. CD24+ cells differ from their counterpart
in their gene profile and are characterized by elevated
extracellular matrix gene expression; this may enable
them to modify the soil of the host tissue in order to in-
vade and form metastasis.
Methods
Cell culture
The mouse mammary cancer cell line, Mvt-1, has been
previously described [16]. Cells were cultured in DMEM(Biological Industries, Beit Haemek, Israel) supplemented
with 10 % fetal bovine serum (Biological Industries) and
antibiotics (penicillin, streptomycin; Biological Industries)
at 37 °C in a humidified atmosphere consisting of 5 %
CO2 and 95 % air.
Animals
Female MKR mice and control mice on an FVB/N back-
ground were used in this study. The MKR mice are
transgenic with a dominant-negative insulin-like growth
factor-I receptor specifically targeted to the skeletal
muscle with a resultant severe insulin resistance and
hyperinsulinemia phenotype [17]. Mice were kept on a
12-hour light/dark cycle with access to standard mouse
chow and fresh water ad libitum. Mice studies were per-
formed according to the protocol approved by the Tech-
nion Animal Inspection Committee. The Technion
holds an National Institutes of Health (NIH) animal ap-
proval license number A5026-01.
Flow cytometry
The following antibodies were used for cell surface stain-
ing of the Mvt-1 cell line, Pacific-Blue-conjugated anti-
CD24, PE-conjugated anti-CD29, AF647 (Alexa Fluor
647)-conjugated anti-CD61/β3 and AF647 (Alexa Fluor
647)-conjugated anti-CD49F (Biolegend, San Diego, CA,
USA): 7-Amino actinomycin D (7-AAD, Biolegend) was
used to gate live cells. Cells were stained at a concentra-
tion of 5 × 106 cells/ml of FACS buffer (PBS containing
0.1 % BSA) for 20 minutes on ice in the dark, after
which the cells were washed twice and resuspended in
FACS buffer containing 7-AAD. Stained cells were ana-
lyzed using the CyAn ADP Instrument (Dako-Cytomation,
Glostrup, Denmark) and the FlowJo 7.25 analysis soft-
ware. Intracellular staining was performed with the
CytoWx/Cytoperm kit (BD PharMingen, San Diego, CA,
USA), after CD24 cell surface staining. Cells were then
washed with the Cytofix solution, and permeabilized with
perm wash for 10 minutes on ice. To detect intracellular
CD24, the antibody was added in combination with perm
wash for 15 minutes on ice. Cells were washed twice and
resuspended in FACS buffer until analysis. Flow cytometry-
based cell sorting for CD24− and CD24+ cells was per-
formed using FACSAria (BD Biosciences, San Jose, CA,
USA).
Tumorspheres
CD24− and CD24+ single cell suspensions were prepared
and plated in nonadherent conditions at 600 cells/cm2
in DMEM F12 HAM medium (Sigma, Rehovot, Israel)
containing 20 ng/ml bFGF (Sigma), 20 ng/ml EGF
(Sigma), 4 μg/ml of Heparin (Sigma) and B-27 supple-
ment (1:50 dilution, GIBCO, Burlington, ON, USA), and
cultured at 37 °C with 5 % CO2. Tumorsphere-forming
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lows: (number of tumorspheres (>50 mm in diameter)
per well/number of cells seeded per well)*100. To assess
self-renewal, primary tumorspheres were centrifuged at
115 × g for 5 minutes, the pellet was resuspended in
300 μl of 0.5 % trypsin/0.2 % EDTA for 3 minutes at
37 °C. Tumorspheres were disaggregated into single cell
suspension with the use of a 25-G needle and syringe,
(trypsin was neutralized with medium containing serum).
Cells were centrifuged at 580 × g for 5 minutes, the pellet
was resuspended in ice-cold PBS, and single cell suspen-
sion was assured under a microscope. Single cells were
plated at the same seeding density that was used in the
primary generation. Tumorspheres (>50 mm in diameter)
were measured after 5 days in culture. Self-renewal was
calculated by dividing the number of secondary tumor-
spheres formed by the number of primary tumorspheres
formed.
Quantitative PCR reaction for cDNA products
Quantitative PCR was performed using Absolute Blue
SYBR-Green ROX mix (Thermo scientific, ABgene, Epsom,
UK). RNA was extracted from treated Mvt-1 cells with the
Total RNA Purification Kit (NORGEN Biotek Corp,
Thorold, Canada) according to manufacturer’s instruc-
tions, followed by single-stranded cDNA synthesis using
the Verso™ reverse transcriptase (Thermo Scientific,
ABgene). The expression measurement of the designated
genes was performed with the Rotor-GeneTM 6000 sys-
tem (Corbett Research, Sydney, Australia) and its soft-
ware, ver. 1.7. The relative gene copy number was
normalized using B2M as the independent internal con-
trol gene, and calculated by the 2^-(Ct(n)-Ct(normalizer))
method, where Ct represents cycle threshold.
Proliferation
Cells were seeded in 96-well plates (1,000 cells/well) for
48 h. Proliferation of the cells was quantitated by the
CyQuant (Invitrogen, Carlsbad, CA, USA) fluorimetric DNA
assay according to the manufacturer’s recommendations.
Knockdown of CD24 by retroviral-based delivery of
shRNA
The shRNA targeting sequence against mouse CD24,
sense (5′-CCCAAATCCAAGTAACGCTACCATTCAAG
AGATGGTAGCGTTACTTGGATTTGTTTTTA-3′) and
antisense (5′-GGGTTTAGGTTCAT TGCGATG GTAA
GT TCTCTACCATCGCAATGAACCTAAACAAAAAT-
3′) or scrambled (control) oligonucleotides were annealed
and then ligated into the BglII and HindIII sites of the
psuper.retro.puro vector (OligoEngine, Seattle, WA, USA).
Retroviral particles were generated and introduced as de-
scribed above.Syngeneic orthotopic tumor models
CD24− and CD24+ cells or knockdown cells were sus-
pended in 100 μl PBS and then injected (5 × 104 cells/
mouse; fewer cells were injected for the serial dilution
experiments) into the left inguinal mammary fat pad
(number 4) of 8-week-old female MKR mice. Tumor
volume was monitored once a week with calipers; vol-
ume was calculated in mm3 by the formula: (width2 ×
length × 0.5). Following sacrifice, tumors were removed
and weighed, then flash frozen in liquid nitrogen and
kept at −80 °C for further analysis.
Generation of the green fluorescent protein-expressing
(GFP) cell line
A construct containing GFP (NV-SV-40-puro-linkek-Ins-
PGK-eGFP, a generous gift from Dr Neufeld, Technion,
Haifa, Israel) sequence was transfected into the Lentiviral
packaging cell line 293FT together with ViraPower
packaging mix (Invitrogen) using the Lipofectamine
2000 reagent (Invitrogen). At 48 h post-transfection,
the supernatant containing the viruses was collected and
filtered through a 0.45-Am syringe filter. Viruses were
used to infect Mvt1 cells in the presence of polybrene
(Sigma, St Louis, MO, USA) at a final concentration of
8 μg/ml. Infected cells were selected and maintained
with 2 μg/ml puromycin. CD24−/GFP+ and CD24+/GFP+
cells were sorted using FACSAria (BD Biosciences).
Tumor dissociation into single cells
Breast tumors were minced with scalpels and transferred
to gentleMACS™ dissociator C-tubes (Miltenyi Biotec,
Bergisch Gladbach, Germany) containing 5 ml of DMEM
(Biological Industries, Beit Haemek, Israel) supplemented
with 10 % FBS (Biological Industries, Beit Haemek, Israel).
C-tubes were then connected to the gentleMACS™ disso-
ciator and tumor dissociation was performed according to
the manufacturer’s instructions. Minced tumors were in-
cubated in the C-tubes for 45 minutes with 300 units/ml
collagenase I (Sigma-Aldrich, Rehovot, Israel) and 2 mg/
ml dispase II (Roche Diagnostics, Mannheim, Germany)
at 37 °C in a humidified atmosphere consisting of 5 %
CO2 and 95 % air. Following incubation a second spin on
the gentleMACS™ dissociator was performed, and the cells
were then filtered through a 40-μm falcon strainer (Becton
Dickinson, Franklin Lakes, NJ, USA).
mRNA-seq
Total RNA was isolated and purified from cells using
the Total RNA Purification Kit (NORGEN Biotek Corp)
according to the manufacturer’s instructions. cDNA li-
braries were prepared using 1 μg of total RNA using the
TruSeq RNA Sample Preparation Kit v2 (Illumina).
Briefly, polyadenylated RNA was purified using magnetic
beads and fragmented according to the manufacturer’s
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the approximately 200-bp fraction was amplified with
15 cycles of PCR. cDNA libraries were subjected to the
Illumina HiSeq 2500 platform to 50-bp single reads
sequencing.
Analysis of mRNA-Seq data
Custom-built software was used to map the reads to the
mouse genome (mm9) and estimate the coverage of each
gene. Briefly, the reads were clipped at both ends (2 at
the 5′ end and 1 at the 3′ end) to remove potentially
error-prone sites. The reads were then mapped to the
genome using a suffix-array-based approach. The me-
dian of coverage across the transcripts was used as an
estimate of gene expression. The expression values were
quantile normalized, and ratios were calculated by com-
paring the mean of samples from CD24− cells against
the mean of samples from CD24+ cells. The noise (or
limits) of expression detection in the mRNA-seq data is
the peak of the distribution of expression values (genes
with high expression are in the long tail of this distribu-
tion). The expression values were regularized by adding
the noise to the expression of each gene before the ratios
were calculated. This ensures that genes with low ex-
pression do not contribute to the list of genes with large
fold-changes. Genes expressed differentially between the
groups were selected by using a p value <0.05 (calculated
by the t test) and fold-change of at least 2 was required
for the gene to be included in the list. The heat map was
generated by custom software R.
Pathway analysis
We used Gene Ontology (GO) analysis [18] to analyze
and compare enriched pathways in CD24− and CD24+
cells. The Gorilla tool was used in order to identify
enriched GO terms. As target list inputs, we used all the
annotated genes as the background for the analysis. GO
terms were selected with a conservative threshold of
false detection rate (FDR) <0.2 and a p value <0.05.
Tail vein metastasis assay
We injected10,000 cells from each subset through the
tail vein of wild-type (WT) mice to assess lung meta-
static activity. Mice were killed 28 days after injection,
lungs were removed and fixed, and macrometastases
were counted under a light-microscope.
Statistical analysis
All data are presented as mean ± standard error of the
mean (SEM). The independent t test and the Mann-
Whitney test was used for statistical analysis of un-
matched groups; the Wilcoxon signed-rank test was used
for matched group comparison, with p values <0.05 con-
sidered statistically significant.Results
Differential expression of CD24 observed within the Mvt1
cells
In order to find heterogeneity and hierarchal organiza-
tion in the mammary carcinoma Mvt1 cell line, we char-
acterized the cell surface expression of CD29, CD61/β3,
CD24 and CD49f, common markers for isolation of
mammary cancer stem cells. Using flow cytometry ana-
lysis, we found uniform expression of CD29, CD61/β3
and CD49f in the Mvt1 cell line, however, CD24 analysis
revealed two distinct populations, CD24− cells (64.1 %)
and CD24+ cells (35.9 %) (Fig. 1a). Next, we double-
sorted the cells into pure (>95 %, as determined by
FACS analysis (Fig. 1b)) CD24− and CD24+ cells. Grown
in complete media, CD24+ cells were widely dispersed in
culture, displaying spindle-like cytoplasm, whereas CD24−
displayed a more rounded epithelial appearance (data not
shown). It is important to note that these differences be-
tween CD24+ and CD24− cells remained constant for
more than 18 passages, whereas a dynamic shift was found
in the Mvt1 cell line as a result of different growth rates of
the two subpopulations. Next, we sought to determine
CD24 expression at the transcript level by quantitative
(q)RT-PCR in these two subpopulations. Indeed, CD24
mRNA levels were moderate but significantly increased in
the CD24+ cells approximately 1.8-fold compared to the
CD24− cells (Fig. 1c). These results suggest that CD24 is
expressed in both subpopulations, while cell surface ex-
pression differs significantly. Indeed, CD24 was expressed
intracellularly in both CD24− and CD24+ subpopulations
(Fig. 1d).
CD24+ cells display in vivo aggressiveness in both WT
and MKR mice
In order to further characterize the CD24− and CD24+
cells, the CyQUANT cell proliferation assay was applied
to compare the proliferation rates of CD24− and CD24+
cells. We observed a significantly enhanced proliferation
rate (>1.7-fold) for CD24+ cells compared to CD24− cells
(Fig. 2a). The tumorsphere assay correlates with tumor
initiating cell ability and can be modified to assess self-
renewal. We used this method to test CD24− and CD24+
ability to form in vitro tumorspheres. Cells were cul-
tured in non-adherent plates for 5 days in serum-free
optimized medium. CD24+ cells formed relatively high
numbers of tumorspheres, which were counted under a
light microscope, and the percentage tumorsphere for-
mation efficiency (TFE) was calculated (Fig. 2b). Primary
tumorspheres generated by the CD24+ cells were disag-
gregated into single-cell suspension; these cells were able
to form secondary tumorspheres, which indicates their
self-renewal ability (data not shown). In striking contrast
to the CD24+ cells, CD24− cells formed no tumorspheres.
Next we tested in vivo the tumorigenic capacity of each
Fig. 1 Isolation and characterization of two Mvt1 subgroups distinguished by their CD24 expression. a Fluorescence-activated cell sorting (FACS)
showing CD29, CD49f, CD61/β3 and CD24 expression in the Mvt1 cell line. b Flow cytometric separation of Mvt1 cells based on CD24 expression.
c RNA was extracted from the sorted CD24− and CD24+ populations for CD24 quantitative RT-PCR analysis. d FACS showing CD24 intracellular
expression. The Mann-Whitney test was performed to compare CD24− and CD24+ cells. *p <0.05
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mouse model to study the effect of hyperinsulinemia on
cancer. These mice are hyperinsulinemic with severe insu-
lin resistance. Importantly these mice are non-obese,
hence, free of the inflammatory and other responses ac-
companied with obesity [19].
CD24− and CD24+ cells were implanted into the
fourth mammary fat pad of WT and MKR female mice.
Interval measurements of tumor volume over a period
of 5 weeks were performed in addition to measurements
of tumor weight at necropsy. Along with previous re-
sults, both CD24− and CD24+ cells formed significantly
larger tumors in the MKR mice compared to WT mice
(2.25-fold and 1.6-fold larger, respectively) (Fig. 2c).
Moreover, CD24+ cell tumors had an enhanced tumor
growth rate compared to the CD24− cell tumors in both
WT (3.8-fold) and MKR mice (2.75-fold) (Fig. 2c). Ter-
minal tumor weights confirmed these results; both
CD24− and CD24+ cells formed significantly larger tu-
mors in the MKR mice (2.6-fold and 1.7-fold, respect-
ively). In addition, in both WT and MKR mice CD24+
formed significantly larger tumors compared to theCD24− cells (3.99-fold and 2.66-fold fold, respectively)
(Fig. 2d).
Low levels of CD24 are sufficient to maintain
tumorigenicity properties
To investigate whether CD24 serves only as a marker for
tumorigenicity or is functionally involved in the induc-
tion of mitogenic pathways, we knocked down CD24 in
the CD24+ subpopulation. The CD24 mRNA levels were
significantly reduced following induction with the corre-
sponding shRNA (Fig. 3a) and FACS analysis demon-
strated a reduction in CD24 expression at the protein
level (Fig. 3b). CD24 knockdown did not affect the pro-
liferation rate of the cells, (a non-significant reduction of
17 % in the CD24+/CD24-KD cells compared to the
CD24+/control cells) (Fig. 3c) nor the TFE percentage
(5.85 vs 6.67 for the CD24+/control and CD24+/CD24-
KD, respectively) (Fig. 3d). Although CD24 knockdown
had no in vitro effect on the cells, we next determined
its role in mammary tumor growth in vivo. CD24+/con-
trol cells and CD24+/CD24-KD cells were injected into
the fourth mammary fat pad of WT mice after a period
Fig. 2 CD24+ cells display in vivo aggressiveness in both wild-type (WT) and MKR mice. a 1*103 CD24− and CD24+ cells were seeded and grown
in full medium for 2 days, and relative proliferation rate between the cells was determined using the Cyquant proliferation assay. b Representative
photomicrographs of a tumorsphere (>50 um diameter) grown from CD24− and CD24+-single cells in non-adherent culture for 5 days (upper
panel). Percentage tumorsphere formation efficiency (TFE %) comparison between CD24− and CD24+ (lower panel). The Mann-Whitney test was
performed to compare CD24− and CD24+ cells (*p <0.05). c CD24− and CD24+ cells were injected into the fourth mammary fat pad of 8-week-
old virgin WT and MKR mice (50,000 cells/mouse), and tumor volume was measured during a 5-week period. d Tumor weights were measured at
necropsy. The Mann-Whitney test was performed to compare CD24− and CD24+ tumors (*p <0.05, and to compare tumors in WT and MKR mice
(#p <0.05)
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(824 mm3 and 701 mm3, respectively) (Fig. 3e).
CD24− cells construct the bulk of the tumors cells
originating from both CD24− and CD24+ cells
To further explore CD24+ stem/progenitor-cell proper-
ties, we injected CD24+/GFP+ and CD24−/GFP+ cells
into the mammary fat pad of WT and MKR female mice.
After 5 weeks, tumors were harvested and dissociated
into single-cell suspensions and GFP+ cells were ana-
lyzed by FACS for CD24 and CD49f expression (Fig. 4a).
The CD24/CD49f profile of CD24−/GFP+ resulting tu-
mors was nearly identical to that of the parental inocu-
lated cells; nearly 100 % of the analyzed GFP+ cells
remained CD24−/CD49f+ (Fig. 4b) in both WT andMKR mice. However, the CD24/CD49f profile of GFP+
cells dissociated from CD24+/GFP tumors showed a
drastic shift in CD24 expression. The CD24+/GFP+ inoc-
ulated cells gave rise to CD24− cells in WT mice (70 %)
and MKR mice (approximately 62 %), whereas less than
40 % remained CD24+ in both groups of mice. Both
CD24− and CD24+ cells remained CD49f+ (Fig. 4b).
CD24+ cells differentiate in vivo into CD24− cells
In our breast cancer model, mammary tumors became
palpable within 14–21 days. To provide solid evidence
for the differentiation process observed in Fig. 4b and to
determine whether the abundance of CD24− cells follow-
ing the injection of CD24+ cells is an early event in tumor
progression, CD24− and CD24+ cells were injected into
Fig. 3 Low levels of CD24 are sufficient to maintain tumorigenicity properties. a Quantitative RT-PCR analysis of CD24 mRNA in cells infected with
control or CD24 shRNA as indicated. b Fluorescence-activated cell sorting analysis of CD24 expression in cells transfected with control or CD24
shRNA. c 1*103 CD24+/control and CD24+/CD24-KD cells were seeded and grown in full medium for 3 days; the relative proliferation rate
between the cells was determined using the Cyquant proliferation assay. d Representative photomicrographs of a tumorspheres (>50 um diameter)
grown from CD24+/control and CD24+/CD24-KD single cells in non-adherent culture for 5 days (upper panel). Percentage tumorsphere formation
efficiency (TFE %) comparison between CD24− and CD24+ (lower panel). e Cells were injected into the fourth mammary fat pad of 8-week-old virgin
wild-type mice. Tumor volume was measured at necropsy. The Mann-Whitney test was performed to compare CD24+/control and CD24+/CD24-KD
cells (*p <0.05)
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days, tumors were harvested and cancer cells were ana-
lyzed by FACS as described earlier for CD24 expression.
As expected, injection of CD24− cells resulted in an al-
most pure CD24− population whereas approximately 40 %
of the cancer cells found in the CD24+ inoculated tumors
were CD24− cells (Fig. 5b, upper panel). Next we tested
whether CD24+ cells reduce CD24 expression and main-
tain tumorigenic phenotype as CD24− cells or indeed
differentiate into the distinct CD24− subpopulation. CD24−
and CD24+ cells that were extracted from CD24+ inocu-
lated tumors were sorted and subjected to cell culture
growth along with CD24− cells that were extracted from
the CD24− inoculated tumors (Fig. 5b, lower panel) and
were characterized for morphology. Grown in adherent
culture, both CD24− subpopulations displayed a similar
phenotype with flatter, more rounded epithelial cells,
whereas the CD24+ cells had distinct mesenchymal-like
morphology with more elongated cytoplasm (Fig. 5c). The
in vitro phenotype of the cells was tested and as expected,
extracted CD24+ cells had both an enhanced proliferationrate and tumorsphere forming efficiency compared to
CD24− cells that were extracted from both CD24− and
CD24+ tumors (Additional file 1: Figure S1).
Gene expression analysis reveals extracellular matrix
gene expression for the CD24+ cells
In order to determine if the two Mvt-1 subpopulations
(CD24− and CD24+) gene profile support the distinct
morphology of the groups and can further explain the
tumorigenic capacity of the CD24+ cells, we analyzed the
gene expression profile using RNA-seq. We identified 146
differently expressed genes (p value <0.05, fold-change >2)
between the two groups; 89 genes were upregulated and
57 genes were downregulated in the CD24+ cells com-
pared to the CD24− cells (a list of the top 15 differentially
expressed genes is indicated in Fig. 6a; the full list is in
Additional file 2: Table S1). We found upregulation in
multiple genes associated with cancer growth and inva-
siveness, such as AXL, a tyrosine kinase receptor that me-
diates tumorigenesis and metastasis; AXL was recently
suggested as a potential therapeutic target in breast cancer
AB
Fig. 4 CD24− cells construct the bulk of the tumors cells originating from both CD24− and CD24+ cells. a Experimental strategy scheme. Green
fluorescent protein (GFP)+ CD24− or CD24+ cells were injected into the mammary fat pads. Tumors were harvested and CD24 expression was
evaluated in GFP+ cancer cells. b CD24 and CD49f expression in GFP+ cancer cells from mammary tumors was determined by fluorescence-
activated cell sorting (FACS) analysis
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brane proteins that were recently found to be elevated in
breast cancer and other human malignancies [22] were
significantly elevated in the CD24+ cells. Additionally we
found significantly higher levels of Twist2 in the CD24+
cells, a transcription factor that enhances tumor invasion
by promoting an epithelial-mesenchymal transition [23].
Moreover, we found upregulation of genes that are related
to invasiveness (MRC2, FSCM and SERPINH1) [24–26].
To better characterize the CD24+ aggressive phenotype,
gene ontology (GO) enrichment analysis was applied. Me-
tastasis formation is a multistep process, which requires
detachment and embolization of cancer cells, circulationsurvival, extraversion and proliferation within a new organ
[27]. The top GO terms enriched with a false detection
rate (FDR) <0.5 in the CD24+ cells were associated with
components of the extracellular matrix (ECM) and cell
adhesion (Fig. 6b). Quantitative RT-PCR was used to
independently validate the RNA-seq analysis results
(Additional file 3: Figure S2). GO terms, GO:0045785 ~
positive regulation of cell adhesion and GO:0005578 ~
proteinaceous extracellular matrix (Fig. 6c) were found
to be enriched in the CD24+ cells. These pathways were
recently reported to be upregulated in distinct popu-
lations of circulating cancer cells [28]. This analysis
suggests that CD24+ cells possess tumor-initiating
Fig. 5 CD24+ cells differentiate and give rise to CD24− cells in vivo. a Experimental strategy scheme. CD24− or CD24+ cells were injected into the
mammary fat pads; after 3 weeks, tumors were harvested and CD24 expression was evaluated. b CD24 expression in cancer cells from mammary
tumors was determined by fluorescence-activated cell sorting analysis (upper panel), and CD24− and CD24+ from CD24+ inoculated tumors were
sorted into a pure population (lower panel). c Different phenotypes for each group shown on phase-contrast bright field images of cells grown in
adherent culture
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primary tumor site but also at a distant site by en-
hanced transendothelial invasion efficiency and matrix
remolding at the host tissue. It is important to note that
GO terms were not found for the CD24− enriched genes
with an FDR <5.CD24 cells are highly metastatic cells with enriched stem/
progenitor properties in vivo
To confirm CD24+ cell metastatic phenotype, we used
the tail vein metastasis assay. Inoculation of each cell
subset into the tail vein of WT mice revealed signifi-
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Fig. 6 Gene expression analysis reveals extracellular gene expression for the CD24+ cells. a Top 15 alternated genes between CD24− and CD24+
(p value <0.05). b Enriched Gene Ontology (GO) terms in CD24+ cells. c Gene set enrichment analysis display strong association between CD24
and the proteinaceous extracellular status matrix gene set. d Expression heat map of CD24− and CD24+ cells. FDR false detection rate
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frequency of larger lung lesions following CD24+ cells
inoculation (Fig. 7a). To further establish the tumori-
genic capacity and progenitor/stem-like features of the
CD24+ cells, CD24- or CD24+ cells were injected into
WT mice as a dilution series (Fig. 7b). CD24+ cellsformed mammary tumors in 83 % of the injection with
as few as 100 cells, whereas CD24− cells generated mam-
mary tumors only in 33 % of the cases. These data pro-
vide clear evidence for the tumor-initiating properties of
the CD24+ cells which enable them to generate a sup-
ported niche to proliferate in the host tissue.
AB
Fig. 7 CD24 cells are highly metastatic cells with enriched stem/progenitor properties in vivo. a Lung metastasis after 4 weeks of inoculation of
10,000 cells into the tail vein of wild-type (WT) mice (upper panel); average macrometastases per lung in each group (lower panel). The Mann-Whitney
test was performed to compare the groups (*p <0.05). b Cell number from the indicated population was injected into the fourth mammary fat pad of
WT mice, and mammary tumor formation was monitored for a period of 5 months
Rostoker et al. Breast Cancer Research  (2015) 17:78 Page 11 of 14Discussion
Breast tumors comprise heterogeneous cell populations
that can be characterized and isolated with specific cell
surface markers [29, 30]. CD24, a known marker for
mammary stem and progenitor cells, was proven useful
to enrich mammary cancer stem cells [31]. CD24+ cells
were shown to be highly tumorigenic, with capability to
form mammary tumors even when implanted in low
numbers [9, 32]. From a clinical perspective, CD24 was
recently suggested as a prognostic marker for invasive
breast tumors and has been associated with shortened
disease-free survival [33, 34]. Here we studied the poten-
tial role of CD24 in the vascular epithelial growth factor
(VEGF)/c-myc mutated Mvt-1 cell line. We report here
that CD24 serves as a cell surface marker for highly
metastatic tumorigenic cancer cells. Moreover, we dem-
onstrated that the cancer process is orchestrated by
stem/progenitor-cancer cells that account for tumor het-
erogeneity that is evoked by microenvironment stimuli.
Using RNA-seq analysis we revealed a unique gene sig-
nature for the CD24+ subset, with elevated expression of
extracellular matrix genes that support the highly meta-
static properties of these cells. These results suggest that
the extracellular matrix genes are new therapeutic tar-
gets for invasive tumors.
CD24 expression is abundantly expressed in human
solid tumors; its expression is associated with high
tumorigenic capacity and worse prognosis [35]. The role
of CD24+ cells in breast tumors is unclear, whereas stud-
ies have shown that CD24− cells are widely described as
tumor initiating cells with stem/progenitor-like properties[15, 36]. Others have demonstrated that this CD24 pheno-
type is not universal for all cancer models but it is more
diverse and is affected by the driver mutation [4].
In the present study, we found heterogeneity within
the Mvt1 cells by characterizing the cell-surface expres-
sion of CD24; we isolated two distinct subpopulations,
CD24− and CD24+ cells. Along with other studies, CD24+
cells have been found to have higher proliferation rates
[37], however, the underlying mechanism remain unclear.
CD24 has already been suggested as a surface marker of
mammary stem and progenitors cells [9]. Using the
tumorsphere assay, we demonstrated that the CD24+ sub-
population is enriched with early stem/progenitors cells
with self-renewal properties. Next, we tested the tumori-
genic potential of these distinct populations in both WT
and MKR mice. The MKR female mice serve as an ideal
model to isolate insulin mitogenic effects; accelerated
mammary gland development was found in these hyperin-
sulinemic female mice [17, 19]. Furthermore, orthotopic
mammary tumors displayed significantly accelerated
growth in these mice compared to WT mice [38, 39]. We
report here that CD24+ cells are highly tumorigenic, form-
ing significantly larger tumors in both WT and MKR
female mice. Although CD24+ cells display high tumori-
genic capacity, it remains to be determined whether CD24
serves as a marker for tumorigenicity or if it is functionally
involved in tumorigenesis. CD24 is mostly considered as
an adhesion molecule; by interacting with p-selectin.
CD24 it promotes the initial steps of cell migration, and
its expression in breast tumors is associated with metasta-
sis [34, 40].
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in intracellular signaling despite the lack of an intracellu-
lar domain [41–43]. Using shRNA technology we were
able to determine that in VEGF/c-myc mutated cancer
cells and in the context of breast cancer, CD24 could
serve as a key marker to identify a subpopulation of
tumorigenic cancer cells, however it is not functionally
involved in the induction of mitogenic pathways. CD24+/
CD24-KD cells remained highly proliferative, with ability
to form tumorspheres with high efficiency. Importantly,
CD24-KD had no effect on tumor growth, as implantation
of both CD24+/control and CD24+/CD24-KD cells formed
rapidly growing tumors. It was recently demonstrated that
CD24−/− cells are able to functionally reconstitute cleared
mammary fat pads [44]. These findings, along with our re-
sults, suggest CD24 is mainly a marker in the mammary
epithelium. However, these data cannot absolutely exclude
a role for CD24 in mediating the metastatic process.
Whether it is the result of clonal evolution or hierarchical
organization that follows the cancer stem cell model,
mammary tumors along with other solid tumors consti-
tute phenotypically and functionally heterogeneous cell
populations [6, 45, 46]. With the tumorsphere assay we
identified stem/progenitor activity and self-renewal prop-
erties in the CD24+ cells in vitro. We next tested these
properties in vivo, having hypothesized that CD24+ cells
can differentiate and give rise to CD24− cells. To validate
this, we implanted CD24+/GFP+ cells into the mammary
fat pad of both WT and MKR mice. FACS analysis of the
labeled cancer cells revealed that CD24+ cells fuels the
cancer process by giving rise to the CD24− cells that com-
prise the tumor bulk.
Next, we confirmed that CD24− cells that were extracted
from the CD24+ tumors were morphologically and func-
tionally distinct from their CD24+ counterparts. Unlike
the CD24+ cells, these CD24− cells (that originated in vivo
from the CD24+ cells) displayed a flatter, more rounded
epithelial phenotype as oppose to the mesenchymal-like
morphology of the CD24+ cells. These data are consistent
with the concept of cancer stem cells having intra-tumor
hierarchical organization as a result of cancer cell differen-
tiation [47]. These findings, suggest that mammary tumors
develop in a multi-step process, which is dictated by
CD24+ cells that demonstrate directed plasticity towards
the differentiated CD24− cells. Moreover, the presence of
about 30 % of CD24+ cells in the CD24+ inoculated tu-
mors, suggests that the CD24+ cells are capable of under-
going asymmetric divisions, thus, expanding both CD24+
and CD24− lineages. It is important to note that CD24+
cells were not able to differentiate in vitro even when co-
cultured with tumor-derived fibroblasts (data not shown).
Other tumor microenvironment factors should be evalu-
ated in order to determine which extrinsic mechanisms
promote cancer cell differentiation.In order to identify transcripts and pathways that may
elucidate the enhanced tumorigenesis upon CD24+ cells
implantation and may serve in the future as therapeutic
targets, we compared the CD24− and CD24+ cellular
transcriptome. Our study identified 157 candidates with
divergent expression between these two groups. Genes
that are associated with the immature state (Tmem176b,
Tmem176a, ATF5) [22, 48] were significantly elevated in
the CD24+ cells. Our analysis also identified upregula-
tion in genes that promote proliferation (AXL and
DDR2) [20, 49], migration and invasion (MRC2, FSCM and
SERPINH1) [24–26], and immune response-associated
genes (SLPI and CHAC1) [50, 51]. Most elevated path-
ways found in the CD24+ are involved in matrix formation
and remodeling. The GO: 0005578 ~ proteinaceous extra-
cellular matrix term was recently identified as common to
distinct circulating cancer cell populations [28]. This find-
ing suggests that CD24+ cells possess highly metastatic
and tumor-initiating properties. We confirmed these find-
ings in vivo with the tail vein metastasis assay and by lim-
ited dilution transplantation we provided clear evidence
for the stem-like properties of the CD24+ cells.
Conclusions
Taken together, our findings demonstrate that CD24 can
serve alone as a marker to identify highly tumorigenic
cancer cells with early stem/progenitor-cell properties.
Furthermore, CD24+ cells are driven to differentiate in
response to intra-tumor stimuli into a distinct CD24−
cell population, thus, creating intra-tumor heterogeneity.
Moreover, we reveal here key genes as new therapeutic
targets in invasive breast tumors.
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Additional file 1: Figure S1. Ex vivo phenotype of CD24− and CD24+
cells. Proliferation rates and percentage tumorsphere formation efficiency
(TFE) of CD24− cell extracted from CD24− developed tumors and CD24−
and CD24+ cells extracted from CD24+ developed tumors were
compared. A Cells were seeded and grown in full medium for 2 days,
and the relative proliferation rates between the cells were determined
using the Cyquant proliferation assay. B Representative photomicrographs
of a tumorspheres (>50 um diameter) grown from CD24− and CD24+ single
cells in non-adherent culture for 5 days (upper panel). TFE (%) comparison
between CD24− and CD24+ (lower panel).
Additional file 2: Table S1. Differentially expressed genes between
CD24+ and CD24− cells.
Additional file 3: Figure S2. Differential gene expression for the CD24−
and CD24+ cells by qRT-PCR. RNA was extracted from independent sam-
ples of CD24− and CD24+ cells, cDNA was synthesized, and relative mRNA
expression of the indicated genes was determined using qRT-PCR.
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